Peptide reagent enabling a primary Epstein-Barr virus infection to be detected by testing for the corresponding antibodies, and method for using this reagent
US6337180B1 · kind B1 · utility
6Cited by
4References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 15, 1997 |
| Grant date | Jan 8, 2002 |
| Priority date | — |
| Expiry date | Aug 15, 2017 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2710/16222
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The use of a peptide reagent for detecting the presence or absence of a primary Epstein-Barr virus infection in a patient by testing for IgM antibodies, recognizing said reagent, in a biological sample from the patient according to a per se known method based on the formation of at least one antigen-antibody complex, is disclosed. The reagent contains a peptide recognized by at least one antibody to a peptide having the sequence of formula (II): Leu Glu Ile Lys Arg Tyr Lys Asn Arg Val Ala Ser Arg Lys Cys Arg Ala Lys Phe Lys Gln. The reagent enables such a primary infection to be detected very early.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.